Tonix Pharmaceuticals (TNXP) Life Sciences Virtual Investor Forum summary

Commercial launch and organizational transition

• Successfully launched a new fibromyalgia treatment, Tonmya, after 15 years of development, marking the first new therapy for the condition in over 15 years.

• Built commercial infrastructure by acquiring migraine products and establishing a sales force of about 90 representatives, with omnichannel outreach to healthcare providers and some direct-to-consumer efforts.

• Early physician feedback is generally positive, with adoption across rheumatologists, primary care, pain specialists, and neurologists, and prescriptions geographically dispersed.

• Patient access programs, including samples and co-pay support, are in place to facilitate adoption.

• Key launch metrics tracked include total and new prescriptions, number of unique prescribers, and refill rates, with growth currently linear but on track.

Market positioning and physician education

• Tonmya is positioned as a first-line, monotherapy option for fibromyalgia, relevant to modern diagnostic criteria and suitable for a broad patient population.

• The product is differentiated from older therapies by being studied under updated 2016 ACR criteria, addressing both primary and secondary fibromyalgia.

• Commercial strategy includes dynamic targeting of prescribers based on real-time data and feedback.

• Physician education on sleep disturbance is handled primarily by medical affairs in response to inquiries, not as a core sales message.

Access, reimbursement, and financial outlook

• Engaged in ongoing negotiations with payers, balancing the need for coverage with maintaining reasonable rebate levels.

• Focused on demonstrating prescription demand to support favorable formulary placement, especially as a non-opioid analgesic for chronic pain.

• Reported $208 million in cash at year-end, providing a one-year runway to fully fund the launch and pipeline development.